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ABSTRAK 
Preeclampsia (PE) terus menyebabkan kematian dan morbiditi dalam kehamilan. 
Antibodi antifosfolipid (APA) diketahui sebagai pencetus proinflamatori dan 
mekanisme terjadinya trombosis. Hubungan antara PE dan APA mula disyaki 
disebabkan oleh kadar PE yang tinggi pada wanita yang menghidapi sindrom 
antifosfolipid (APS). Ia tidak diketahui sama ada jenis APA yang jarang ini terdapat 
dalam pesakit PE terutamanya dalam populasi kami. Tujuan kajian ini adalah untuk 
mengesan antibodi antiannexin V (antiAnV) dan antiphosphatidyl inositol (aPI) dalam 
pesakit PE. 
 
Kajian ini telah dijalankan di HSIJB dan HUSM dari Januari 2013 hingga Disember 
2014. Lapan puluh empat sampel telah dikumpulkan dengan bilangan pesakit PE dan 
bukan PE adalah sama dan dianalisa untuk ujian kiraan sel darah (FBC), ujian 
pembekuan darah, profil biokimia dan antiAnV dan aPI. Antibodi ini dianalisa dengan 
menggunakan kaedah ELISA. 
 
AntiAnV IgG telah dikesan dalam satu kes PE tahap bahaya dalam kehamilan kembar 
semasa tempoh mengandung dan selepas bersalin (lima bulan). Tiada antibodi lain yang 
dikesan. Kes ini didiagnos dengan PE yang bermula awal dan kelahiran pramatang pada 
33 minggu kehamilan kerana tahap PE yang bahaya. Ujian aPTT beliau menunjukkan 
masa untuk penghasilan darah beku yang singkat (19 saat) selaras dengan keputusan 
kami yang purata aPTT menunjukkan perbezaan yang ketara antara PE yang sederhana 
dan teruk (p = 0.007). 
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APA yang jarang ini tidak dikesan dalam pesakit PE dan bukan PE yang lain. Walau 
bagaimanapun, terdapat perbezaan yang ketara dalam nilai IgM aPI antara PE dan 
bukan PE. Pertalian dengan APS tidak dapat dipastikan kerana ia adalah jenis IgM. 
Walau bagaimanapun, kehadiran IgM dalam kehamilan walaupun sebagai antibodi 
sementara adalah penting dari segi klinikal kerana ini berkaitan dengan kekalutan 
sistem imun dalam tempoh kehamilan dan boleh menjadi pencetus kepada PE. 
 
Dari kajian ini, kelaziman APA yang jarang ini pada pesakit PE adalah rendah (2.4%). 
Walau bagaimanapun, kajian yang lebih besar diperlukan bagi data yang lebih tepat dan 
lebih banyak APA yang diuji untuk perkaitan yang lebih baik dan meningkatkan 
pemahaman tentang penyakit ini. Komplikasi klinikal yang lain perlu diambilkira dan 
dikaji untuk membantu dalam perawatan pesakit PE dengan lebih baik supaya morbiditi 
dan mortaliti dapat dikurangkan. Dalam kes PE tahap bahaya, ujian aPTT yang singkat 
adalah suatu keputusan yang penting dan perlu diterokai terutama pada pesakit PE yang 
dikesan positif APA.  
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ABSTRACT 
Preeclampsia (PE) continues to cause mortality and morbidity in pregnancy. 
Antiphospholipid antibody (APA) is known to induce proinflammatory and 
prothrombotic mechanisms. Relationship between PE and APA was first suspected due 
to high rate of PE in women with antiphospholipid syndrome (APS). It is not known 
whether rare types of APA are present in PE patients especially in our populations. The 
aim of our study is to detect antiannexin V (antiAnV) and antiphosphatidyl inositol 
(aPI) antibody in PE patients.  
 
A cross sectional study was done at HSIJB and HUSM from January 2013 to December 
2014. Eighty four samples were collected with equal number of PE and non PE and 
analyzed for FBC, coagulation, biochemical profiles and antiAnV and aPI. These 
antibodies were analyzed using ELISA method. 
 
AntiAnV IgG was persistently detected in one case of severe PE associated with twin 
pregnancy during pregnancy and 5 months postnatal period. No other antibodies were 
detected. This positive case was diagnosed with early onset PE and had preterm 
delivery at 33 weeks gestation due to severe PE. Her activated Partial Prothrombin 
Time (aPTT) was shortened (19 sec) in keeping with our finding of significant different 
aPTT between mild and severe PE (p = 0.007).  
 
APA was not detected in other PE patients and non PE. However, there was a 
significant different of aPI IgM concentration between PE and non PE. The association 
with APS is uncertain as it is IgM type. However, the presence of IgM in pregnancy 
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even as a transient antibody could be of clinical significance as this is related to 
immune derangement during pregnancy period and may lead to PE development. 
 
From this study, the prevalence of rare types of APA in PE patients is low (2.4%). 
However, larger studies are needed for more accurate data and to include more APA for 
better correlation and understanding of the disease. Other clinical outcomes need to be 
evaluated in order to provide better management of PE so that the maternal and fetal 
morbidity and mortality can be minimised. Shortened aPTT in severe PE is a significant 
finding and need to be explored especially in PE patients with positive for APA. 
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1.0 INTRODUCTION 
 
Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized 
by thrombosis (could be from venous, arterial or/and microvascular), recurrent fetal 
loss or placental dysfunction in association with persistent elevation of 
antiphospholipid antibodies (APA) at least 12 weeks apart. The diagnosis of APS is 
made when at least one clinical criteria and one laboratory criteria is fulfilled. APS can 
occur in pregnant women as well as in non pregnant individuals. 
 
APA are antibodies that directed against phospholipid antigen or protein antigen that 
binds to phospholipid (Giannakopoulos et al., 2007b). Most common APA are lupus 
anticoagulant (LA) and anticardiolipin antibodies (aCL). However there are many other 
APA such as anti-β2-glycoprotein I (anti-β2GPI), antiphosphatidyl serine (aPS), 
antiprothrombin, anti-annexin V (anti-AnV), antiphosphatidyl inositol (aPI), 
antiphosphatidyl glycerol (aPG) and antiphosphatidyl ethanolamine (aPE). The rare 
types of APA which will be tested in this study are antiAnV and aPI. Limited studies 
are available on these rare APA in the literatures and so far no report among the 
Malaysian population regarding these rare APA. 
 
Preeclampsia (PE) is a clinical syndrome which consists of new onset hypertension and 
proteinuria after 20
th
 weeks of gestational period. It affects 3-5% of pregnant women 
worldwide and causes significant mortality and morbidity (Young et al., 2010a). PE is a 
progressive disease. There are different pathophysiologies to explain PE such as 
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microthrombosis, vascular, endothelial inflammation or imbalance of angiogenic and 
antiangiogenic placental factors.  
The diagnosis of PE is made after 20 weeks of gestation when previously normotensive 
women presented with high blood pressure (systolic blood pressure (SBP) ≥ 140mmHg 
or diastolic blood pressure (DBP) ≥ 90mmHg) measured twice 6 hours apart and 
proteinuria ≥ 0.5g in 24 hours. Early onset of PE is defined as the detection of PE 
before 34 weeks of gestation where as late onset of PE is defined as the detection of PE 
at or after 34 weeks of gestation (Geller et al., 2004; Young et al., 2010b).  
 
Recent studies had revealed that APA induced proinflammatory as well as 
prothrombotic mechanisms mainly in recurrent miscarriage and fetal loss, so the similar 
mechanisms could be assumed in APA induced PE (Ferrer-Oliveras et al., 2012).  
Relationship between PE and APA was first suspected due to high rate of PE in women 
with APS. They usually present early in gestation and associated with severe PE.  
 
The outcomes of the pregnancy and fetus of PE mothers can be devastating as PE can 
cause placental insufficiency and leads to miscarriage, preterm delivery, low birth 
weight, fetal distress or stillbirth. It is estimated that 10% of pregnant women with 
recurrent pregnancy loss were positive to APA such as aCL and LA (Atterbury et al., 
1997). First trimester abortions have been reported in almost 50% of untreated 
pregnancies in women with LA and/or medium to high levels of IgG aCL (D Ware et 
al., 1992). Women with positive APA and a prior fetal death had a pregnancy loss rate 
greater than 95% in subsequent untreated pregnancies (D Ware et al., 1992). 
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Post partum complication is rare however it has been observed in the post partum 
period up to 5 weeks post delivery. The complications include pericardial and pleural 
effusions, subclavian thrombosis, pulmonary embolus, thrombocytopenia, pulmonary 
hypertension and cardiomyopathy (Atterbury et al., 1997). 
 
The aim of this study was to investigate the presence of rare APA (antiAnV and aPI) in 
PE patient and compared with normal control subjects including the outcomes of the 
pregnancy. These antibodies were chosen because till date no similar study had been 
done in Malaysia and neighbouring countries. These two antibodies are not favourable 
to researchers however, a few studies showed a significant increased of these antibodies 
in patient with recurrent fetal loss (D'Ippolito et al., 2014). PE could be induced by 
APA as explained by the pathophysiological process in many cellular models and hence 
we could expect the possible contribution of these antibodies to the development of PE 
and its complications.  Hence the clinical significance of these rare antibodies among 
PE patients could be explored.  
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2.1 ANTIPHOSPHOLIPID SYNDROME 
2.1.1 INTRODUCTION 
APS is an acquired autoimmune disorder firstly described in 1983 characterized by the 
presence of APA with at least one clinical symptom either vascular thrombosis or 
obstetric manifestation such as repeated miscarriage. APS can be primary or secondary 
(when it is associated with other systemic disease mainly systemic lupus 
erythematosus), which affects 1 to 20 in every 100,000 women, depending on the 
ethnic origin. The population prevalence of primary APS is uncertain. It is estimated to 
affect about 0.5% of the population. The male: female ratio for primary disease is 1:3.5 
and 1:7 for secondary APS. The mean age at diagnosis is 35 years, where the incident 
in children is very rare (D'Ippolito et al., 2014). 
 
Many studies have been conducted to further understanding of APS. Recent studies had 
established the two distinctions of APS which are obstetric and vascular based on 
observation that i) patients can display either vascular thrombosis with no pregnancy 
complications or, alternatively, obstetric manifestations alone with no vascular 
symptoms and ii) the coexistence of both thrombosis and miscarriage only affects about 
2.5–5% of APS pregnancies. This is because the mechanisms involved are different 
between obstetric and vascular APS (D'Ippolito et al., 2014).  
 
Diagnosis of APS is made based on the presence of clinical criteria of thrombus 
formation with detection of APA. The antibodies in this disorder are directed against 
protein antigens that bind to anionic phospholipids, such as β2-glycoprotein I (β2GPI) 
and prothrombin or directed against anionic phospholipid per se such as cardiolipin and 
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phosphatidyl serine. Thus there are many types of antiphospholipid antibodies which 
have shown to have significant role in promoting thrombus formation in this disorder. 
However, to date only three antibodies (lupus anticoagulant, anticardiolipin and anti β2-
glycoprotein I antibody) are included in the laboratory criteria to diagnose APS and 
they are widely tested in the major hospital laboratories. Table 2.1 shows the criteria to 
diagnose APS in current setting. 
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Table 2.1 Antiphospholipid Syndrome: clinical criteria and laboratory criteria 
(D'Ippolito et al., 2014) 
Clinical criteria Laboratory criteria 
1. Vascular thrombosis 
One or more clinical episodes of arterial, 
venous, or small vessel thrombosis, in any 
tissue or organ. Thrombosis must be 
confirmed by objective validated criteria 
(i.e. unequivocal findings of appropriate 
imaging studies or histopathology). For 
histopathologic confirmation, thrombosis 
should be present without significant 
evidence of inflammation in the vessel 
wall. 
 
2. Pregnancy morbidity 
(a) One or more unexplained deaths of a 
morphologically normal fetus at or beyond 
the 10th week of gestation, with normal 
fetal morphology documented by 
ultrasound or by direct examination of the 
fetus, or 
(b) One or more premature births of a 
morphologically normal neonate before 
the 34th week of gestation because of:  
(i) eclampsia or severe preeclampsia, or  
(ii) recognized features of placental 
insufficiency, or 
(c) Three or more unexplained consecutive 
spontaneous abortions before the 10th 
week of gestation, with maternal anatomic 
or hormonal abnormalities and paternal 
and maternal chromosomal causes 
excluded. 
1. Lupus anticoagulant (LA) present in 
plasma, on two or more occasions at least 
12 weeks apart. 
 
2. Anticardiolipin (aCL) antibody of IgG 
and/or IgM isotype in serum or plasma, 
present in medium or high titer (i.e. >40 
GPL or MPL, or > the 99th percentile), on 
two or more occasions, at least 12 weeks 
apart, measured by a standardized 
enzyme-linked immunosorbent assay 
(ELISA). 
 
3. Anti β2-glycoprotein I antibody of IgG 
and/or IgM isotype in serum or plasma (in 
titer > the 99th percentile), present on two 
or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA. 
 
 
*GPL and MPL is IgG and IgM 
phospholipid unit 
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International classification criteria for this syndrome were proposed in 1998 in Sapporo 
(Japan) and updated in 2006 in Sydney (Australia). At least one clinical manifestation 
together with positive laboratory tests is required to fulfil the classification criteria. 
 
Beyond classical criteria, “non-criteria” clinical and laboratory manifestations should 
be mentioned. Non-criteria clinical findings include: heart valve disease; livedo 
reticularis; thrombocytopenia; nephropathy; neurological manifestations.  Non-criteria 
laboratory findings include: IgG or IgM aCL or anti β2GPI levels in the range of 20 to 
39 GPL or MPL units; IgA aCL and IgA anti β2GPI; aPS and aPE; antiprothrombin 
antibodies (aPT) and antibodies to the phosphatidyl serine–prothrombin complex 
(aPS/PT).  
 
It is not known whether the above mentioned conditions may “predate” the 
development of APS and may be regarded as “pre-APS” manifestations. Until such 
information has been well established they cannot be included in the diagnostic criteria 
because of potential loss of specificity in recognizing APS, which might lead to 
unwarranted treatments (D'Ippolito et al., 2014). 
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2.1.2 PATHOGENESIS OF ANTIPHOSPHOLIPID SYNDROME 
 
Phospholipids are an important component of the cell membranes. They form a lipid 
bilayer in which their hydrophillic (attracted to water) head areas arranged to face the 
aqueous cytosol and the extracellular fluid, while their hydrophobic (repelled by water) 
tail areas faced away from the cytosol and extracellular fluid. The lipid bilayer is semi-
permeable, meaning that only certain molecules are allowed to diffuse across the 
membrane. There are a few major phospholipids such as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS) and 
phosphatidylglycerol (cardiolipin is made of two phosphatidylglycerol and mainly 
exclusively found in inner mitochondrial membrane).   
 
Giannakopoulos et al, 2007a, unveiled a few hypotheses regarding pathogenesis of 
APS when they did studies on mechanism that predispose to thrombosis in APS patient. 
The dominant antigenic targets in APS are β2GPI and prothrombin. Antigenic targets 
other than β2GPI and prothrombin have been identified in APS patients, including 
tissue plasminogen activator (tPA), plasmin, annexin 5 and thrombin. 
 
2.1.2(a) Complement 
 
The possible role of complement activation in APS pathogenesis is suggested by the 
demonstration of increased complement activation products in the plasma of patients 
with APS who have had a cerebral ischemic event, which may be an important 
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mediator in thrombosis pathogenesis, compared with patients suffering from non-APS–
related cerebral ischemia (Giannakopoulos et al., 2007a). 
 
Figure 2. 1   Pathogenic mechanism of complement activation in antiphospholipid 
syndrome (adapted from Pathophysiology of thrombosis and pregnancy morbidity in 
the antiphospholipid syndrome, Oku et al, 2012) 
 
2.1.2(b) Dysregulated activation of platelets, endothelial cells, and monocytes by 
the anti β2GPI Ab/β2GPI complex bound to the cell surface 
 
Anti β2GPI Ab/β2GPI complex has to initially form on the exposed PS before 
interacting with specific platelet receptors to potentiate activation of the platelet leading 
to thrombosis. AnV2 and Toll-like receptors (TLR) family also interact with anti β2GPI 
Ab/β2GPI complex on the endothelial surface to mediate activation. 
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Antibodies that bind directly towards AnV2 without β2GPI have also been shown to 
associate with the thrombotic manifestations seen in APS patients. They are able to 
directly activate nonstimulated endothelial cells, same to the effect of the anti β2GPI 
Ab/β2GPI complex. However, it is not clear why anti β2GPI Ab/β2GPI complex itself 
cannot induce activation without priming factor in vivo. 
 
Anti β2GPI Ab/β2GPI complex also can activate monocytes to express tissue factors 
and release various pro-inflammatory cytokines leading to thrombosis. However, the 
relevant cell surface receptor has not yet been identified (Giannakopoulos et al., 
2007a). 
 
2.1.2(c) Platelet receptors 
 
Apolipoprotein E receptor 2 (ApoER2) the only receptor of the low-density lipoprotein 
(LDL) family described on platelets, mediates a role in the activation of platelets. This 
receptor was able to coprecipitate with dimerized β2GPI, providing evidence for a direct 
interaction between β2GPI and the receptor (Giannakopoulos et al., 2007a). 
 
2.1.2(d) Endothelial cell receptor 
 
Zhang et al, 2005, demonstrated that β2GPI binding to AnV enabled anti β2GPI 
antibodies (Abs) to activate endothelium, inducing the expression of a procoagulant 
phenotype. Meroni et al, 1998, also noted that anti β2GPI Abs, in the presence of 
β2GPI, are able to activate the nuclear factor-κB (NF-κB) pathway in endothelial cells, 
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leading to the expression of a procoagulant and proinflammatory phenotypes 
(Giannakopoulos et al., 2007a). 
 
Giannakopoulos et al, 2007a, also suggested prothrombotic mechanism based on the 
disruption of the interaction between the anticoagulant factors and the PS surface as 
well as disruption in fibrinolysis. 
2.1.3 PATHOPHYSIOLOGY OF OBSTETRIC ANTIPHOSPHOLIPID 
SYNDROME 
 
Most common manifestation of APS in pregnancy is preeclampsia, eclampsia followed 
by abruptio placenta. It is suggested there is possibility of negative effect of APA 
towards placentation. Normal process requires invasion of trophoblasts into maternal 
endometrial tissues and new vessels formation in decidualized endometrium. The 
trophoblasts will invade up to inner one third of myometrium and the uterine 
vasculature where they will secrete metalloproteinases (MPs), a proteolytic enzyme 
capable to degrade extracellular matrix component. Anti β2GPI Abs can adhere to both 
trophoblasts and human endometrial endothelial cells (HEEC) lead to functional 
damage and poor obstetric outcome. 
 
Yamamoto et al, 1996, suggested that one of the causes of preeclampsia is the 
production of APA that binds to placental villous membrane antigens. Three types of 
APAs were tested in this study; aCL, aPS and antiphosphatidyl choline antibody (aPC). 
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APAs were able to: 
(i) Inhibit syncytiotrophoblast differentiation, as shown by the reduced secretion of 
human chorionic gonadotrophin (hCG); 
(ii) Impair trophoblast invasiveness in an in vitro Matrigel assay. This effect is well 
correlated with a significant inhibition of expression/activity of MPs; 
(iii) Affect the trophoblast expression of integrins and cadherins. These represent 
adhesion molecules, whose expression is regulated during the process of trophoblast 
adhesion and invasion into maternal tissues. In particular it was found that APAs 
decrease alpha 1 integrin and vascular endothelial (VE)-cadherin and up-regulate alpha 
5 integrin and epithelial (E)-cadherin. 
(iv) Block endometrial angiogenesis both in vitro and in vivo, by inhibiting the HEEC 
tube formation and the production of specific factors up-regulated during angiogenesis, 
such as vascular endothelial growth factor (VEGF). Studies on the involvement of 
β2GPI in the angiogenesis showed that, in contrast to the previously reported anti-
angiogenic properties of β2GPI, a cleaved form of β2GPI is able to block the activity of 
angiostatin, a well known inhibitor of angiogenesis. The effect of anti β2GPI antibodies 
on endometrial angiogenesis: whether the observed inhibitory effect is due to an 
imbalance between the intact and the cleaved form of β2GPI still remains to be explored 
(D'Ippolito et al., 2014). 
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Figure 2.2 Effect of APA on placenta (adapted from Miscarriages can be Prevented, 
Reproductive Immunology Associates) 
 
Antiphospholipid antibodies can also cause blood vessels to constrict, causing 
decreased blood flow throughout the circulatory system.  
 
The combination of blood clots and constricted blood vessels may impair blood 
supply to the fetus and placenta resulting in complete fetal demise or growth 
retardation. 
Figure 2.3 Fetal outcome in abnormal blood vessels (adapted from Miscarriages can be 
Prevented, Reproductive Immunology Associates)  
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2.1.3(a) Antiannexin V 
 
AnV is a placental anticoagulant protein expressed on the surface of 
syncytiotrophoblast. It plays an important role as thrombomodulatory and contributes to 
the fluidity of the maternal circulation through the intervillous surface. AntiAnV IgG 
antibodies have been reported with higher frequency in women with unexplained fetal 
loss compared to women with normal pregnancy suggesting that these antibodies may 
represent a risk factor for fetal loss.  
 
A significant elevation of antiAnV has been reported in women with recurrent fetal loss 
via a study done by Sater et al, 2011, compared to controls. However consecutive study 
failed to demonstrate association between antiAnV and the prediction of miscarriage 
thus another factor is proposed to contribute to recurrent fetal loss. A study done by 
Rand et al, 2010, showed there is increased prevalence of antiAnV in women with 
obstetric APS compared to controls. 
 
2.1.3(b) Antiphosphatidyl inositol 
 
Phosphatidyl inositol (PI) is a type of anionic phospholipid and the involvement of aPI 
in the pathophysiology of APS and PE is still debated. Very little study had been done 
in relating this antibody with APS. When this antibody is reported, it is usually 
associated with aCL or aPS. However, there is a report of aPI as the only APA present 
in six young patients with cerebral ischemia of undetermined cause (McIntyre et al., 
2003).  
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2.1.4 PREGNANCY OUTCOMES IN APS 
 
APS in pregnancy can give rise to serious adverse event to the mothers as well as the 
neonates. The clinical outcomes of APS in pregnancy include recurrent abortion, 
intrauterine fetal death, intrauterine growth retardation (IUGR), maternal arterial and 
venous thrombosis and PE (Munday and Jones, 1993). Hence, correct and early 
diagnosis is important for the maternal and fetal wellbeing. Many studies had been 
done and some are still going on for better understanding of the disease and better 
management of the patients.  
2.2 PREECLAMPSIA 
2.2.1 INTRODUCTION 
 
Preeclampsia is a systemic syndrome which can affect morbidity and mortality of a 
pregnant mother as well as the fetus. It is diagnosed after 20 weeks of gestation when 
the patient presented with persistent hypertension on two occasions and proteinuria. 
Study had suggested of imbalance of placental angiogenic and antiangiogenic factor as 
a pathogenesis for preeclampsia. Delivery of the placenta is the only known treatment 
suggestive of placental aetiology (Voto et al., 1999; Steegers et al., 2010; Young et al., 
2010b; Ahmed, 2011).  
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2.2.2 PATHOGENESIS OF PREECLAMPSIA  
 
PE is thought to be due to inadequate invasion of placental cytotrophoblast with 
endothelial dysfunction. Study had shown excess of antiangiogenic factors soluble fms-
like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) were released by the placenta 
leading to widespread endothelial dysfunction resulting in hypertension, proteinuria and 
other systemic manifestation of APS (Young et al., 2010a). 
 
In normal pregnancy, cytotrophoblast will invade the myometrial artery for adequate 
placental perfusion. In PE, the cytotrophoblast is unable to invade myometrial artery 
effectively due to alteration in angiogenic pathway (upregulation of sFlt1 and increased 
Transforming Growth Factor (TGF-β) and alteration in expression of VEGF, placental 
growth factor and VEGF Receptor-1 (Young et al., 2010a).  
 
17 
 
 
Figure 2.4 Placentation in normal pregnancy and in PE (adapted from Journal of 
American Heart Association, Powe et al, 2011)  
 
Figure 2.5 sFlt1 and sEng cause endothelial dysfunction by antagonizing VEGF and 
TGF-β1 signalling (adapted from Journal of American Heart Association, Powe et al, 
2011) 
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Other contributory factors to PE are placental hypoxia, immune factors due to paternal 
antigen, renin-angiotensin-aldosterone (RAA) pathway which there is increase 
sensitivity towards angiotensin II leads to vasoconstrictive effect, alteration in placental 
enzymes for example cathecol-o-methyltransferase enzyme deficiency which can lead 
to placental hypoxia and oxidative stress/placental debris which increase in superoxide 
and reduce antioxidant capacity (Powe et al., 2011). 
 
Nitric oxide (NO) is important for angiogenesis. In PE, endothelial dysfunction is due 
to loss of endothelial nitric oxide synthase (eNOS) activity leads to production of 
superoxide instead of NO. This will cause widespread endothelial damage resulting in 
hypertension and proteinuria (Ahmed, 2011). Hemeoxygenase-1 (HO-1) enzymes also 
offer cytoprotection against tissue and cellular injury and protective against ischaemia-
reperfusion injury. Study reported that loss of HO activity leads to placental damage. 
 
AnV antigen is present on trophoblast cells. Anti-AnV Abs can induce apoptosis and 
reduce trophoblast gonadotrophin secretion which can cause defective in placentation 
(Di Simone et al., 2001). This eventually can manifest as clinical symptoms such as PE. 
 
Antiphosphatidyl inositol is rarely of interest of most studies. However, study showed 
that the level of this antibody is increased in cases like recurrent fetal loss (Ulcova-
Gallova, 2012). Assuming the pathophysiology is due to abnormal placentation same as 
in PE, this study will help further in understanding the significance of this antibody in 
PE patient. 
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2.2.3 CLINICAL OUTCOMES OF PREECLAMPSIA 
 
Preeclampsia is one of the leading causes of maternal and neonatal morbidity and 
mortality. Maternal impacts on PE includes impairment of the renal function, or 
complicated with seizure (eclampsia); or development of HELLP syndrome (hemolysis, 
elevated liver enzymes and low platelet) or the worst outcome is mortality. This 
condition is reversible with the delivery of placenta (Voto et al., 1999; Steegers et al., 
2010; Young et al., 2010a; Ahmed, 2011; Powe et al., 2011).  
 
Placental abruption, ascites, hepatic infarction, hepatic rupture, pulmonary edema and 
intra-abdominal bleeding are all severe manifestation of PE. PE targeted endothelium 
as its pathogenesis hence, resulting in systemic effect affecting organ such as liver, 
kidney and brain. Stroke and cerebral haemorrhage are examples of cerebrovascular 
accidents which becomes major cause of eclampsia-related maternal death (Powe et al., 
2011).  
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Figure 2.6 Summary of pathogenesis of PE (adapted from the journal American Heart 
Association, Powe et al, 2011) 
 
Fetal outcomes include IUGR, low birth weight, preterm delivery, neonatal 
intraventricular haemorrhage, respiratory distress syndrome and the worst case is fetal 
death (Buchbinder et al., 2002). As the pathophysiology is due to abnormal 
placentation, it will impair the supply of the oxygen and the nutrients from the mother 
to the fetus for normal fetal development. In this study, I will only see the weight of the 
baby in view of the limitation I had. 
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2.3 ANTIPHOSPHOLIPID SYNDROME IN PREECLAMPSIA 
PATIENT 
 
Obstetric APS is a combination of thromboembolic events, APA and obstetric 
complications (Galli et al., 2003). It can be divided into primary and secondary in 
which the secondary cause is usually due to underlying autoimmune disease such as 
Systemic Lupus Erythematosus (SLE). There are studies that suggested association 
between APS with PE (Munday and Jones, 1993; Ahmed, 2011; D'Ippolito et al., 2014; 
de Jesus et al., 2014).  
 
One of the causes of PE is due to the production of APA that binds to placental villous 
membrane antigen and can cause placental villous dysfunction and abnormal fetal 
growth (Yamamoto et al., 1996). Apart from the similar pathophysiology between these 
two entity, the clinical outcomes to the mother as well as the fetus also almost the same.  
 
To date, there is not a single test meets the standard to predict PE. However, 
combination of ultrasound Doppler for uterine artery, placental thickness and 
homogeneity, serum pregnancy-related plasma protein A, serum free placental growth 
factor, body mass index, presence of nulliparity or previous PE can give high 
specificity and sensitivity in predicting early PE (Steegers et al., 2010) 
 
This study is targeting the rare APA, anti-AnV and aPI, to observe association with PE 
and fetal weight as the clinical outcome.  
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3.0 OBJECTIVES OF THE STUDY 
3.1 GENERAL OBJECTIVE 
 
To study the laboratory and clinical significance of rare APA (antiAnV and aPI) in 
pregnant women with PE and normal pregnant women in Hospital Universiti Sains 
Malaysia (HUSM) and  Hospital Sultan Ismail, Johor Bahru (HSIJB). 
 
3.2 SPECIFIC OBJECTIVES 
 
1. To determine the prevalence of rare APA in PE patients in HUSM and HSIJB. 
2. To determine the proportion of the presence of APA among PE and normal 
pregnant women in HUSM and HSIJB during pregnancy and 2 months post 
partum.  
3. To compare the proportion of the presence of rare APA among different groups 
of PE in HUSM and HSIJB. 
4. To study the frequency of clinical complication and abnormal haematological 
parameters among PE patients. 
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4.0 MATERIALS AND METHOD 
4.1 Study design 
 
This comparative cross sectional study was conducted in Hospital Universiti Sains 
Malaysia, Kubang Kerian, Kelantan (HUSM) and Hospital Sultan Ismail Johor Bahru 
(HSIJB) over two years period from January 2013 until December 2014. Protocol for 
this study was approved by Medical Research and Ethics Committee, Ministry of 
Health Malaysia and School of Medicine Science Research and Ethical Committee. All 
subjects gave written consent (see Appendix). 
4.2 Sampling method 
4.2.1 Sources population for cases 
 
The source population of the subjects was all pregnant women with PE and attended 
Obstetrics and Gynaecology (O&G) department in HSIJB and HUSM from January 
2013 until December 2014. 
4.2.2 Sampling frame for cases 
 
The sampling frame was those with PE and fulfilled the inclusion and exclusion 
criteria. 
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4.2.3 Inclusion criteria for cases 
 
The inclusion criteria were antenatal mothers who were diagnosed to have PE (after 
20
th
 weeks of gestation). The patients must be previously normotensive women 
presented with high blood pressure (systolic blood pressure (SBP) ≥ 140mmHg or 
diastolic blood pressure (DBP) ≥ 90mmHg measured twice (6 hours apart) associated 
with proteinuria ≥ 0.5g in 24 hours. Severe preeclampsia is defined as SBP ≥ 170 
mmHg or DBP ≥ 110 mmHg (acute hypertensive crisis in pregnancy) on two occasions, 
with proteinuria of 1 g/day or DBP ≥ 100 mmHg on two occasions, with significant 
proteinuria (1+ on dipstick), with two or more signs or symptoms of imminent 
eclampsia, which include: 
a. severe headache 
b. visual disturbance 
c. epigastric pain and/or vomiting 
d. clonus 
e. papilloedema 
f. liver tenderness 
g. platelet count below 100,000 x 10
9
/l 
h. abnormal liver enzymes  
i. HELLP syndrome (haemolysis, elevated liver enzymes, low 
platelets) 
j. intrauterine growth restriction (IUGR) 
k. pulmonary oedema and / or congestive cardiac failure 
